Viyash Scientific Publishes Q3FY26 Unaudited Financial Results
Viyash Scientific Limited published its unaudited financial results for Q3FY26. The company is undertaking significant capital expenditure, including a new ₹200 crore API manufacturing facility in Hyderabad, a ₹200 crore unit in Visakhapatnam, and a ₹120 crore project in Gujarat. These projects are expected to be completed between March 2026 and March 2027.
The announcement details significant capital expenditure for new manufacturing facilities, which indicates future growth potential. The publication of financial results is a standard disclosure, but the scale of the planned investments suggests a medium-term impact on the company's operations and financial standing.
The announcement is a routine publication of financial results and details ongoing capital expenditure projects. While the capex indicates future growth, there are no specific financial performance highlights or significant positive/negative news to assign a strongly positive or negative sentiment.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has published extracts of its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The advertisements were published on February 07, 2026, in The Financial Express (English) and Nava Telangana (Telegu) newspapers. The company provided a QR code for accessing the full financial results.
The announcement details significant construction and development activities. A new manufacturing facility is being established in Hyderabad, Telangana, with a project cost of approximately ₹200 crore. This facility will focus on producing active pharmaceutical ingredients (APIs) and intermediates, with a capacity of 65 kl of drug substance and 20 kl of intermediates. The project is expected to be completed by March 2027, with an estimated investment of ₹540 crore for the entire project, including land and building costs.
Furthermore, the company is developing a new API manufacturing unit in Visakhapatnam, Andhra Pradesh. This unit will produce 200 kl of drug substance and 65 kl of intermediates, with an investment of approximately ₹200 crore. Additionally, a new facility in Gujarat for producing 20 kl of intermediates and 50 kl of drug substance is also underway, with an estimated investment of ₹120 crore. The Visakhapatnam unit is slated for completion by March 2026, and the Gujarat unit by March 2027. The company has also undertaken a project for a new manufacturing plant in Gujarat, involving an investment of ₹200 crore. The Visakhapatnam unit's construction is expected to be completed by March 2026, with an estimated investment of ₹200 crore.
The company has also reported progress on other projects, including a new manufacturing plant in Gujarat, which involves an investment of ₹200 crore and is expected to be completed by March 2027. The Visakhapatnam unit is scheduled for completion by March 2026. The company is also expanding its manufacturing capacity in Visakhapatnam, with an investment of ₹200 crore. The Gujarat plant expansion is expected to be completed by March 2027.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.